Liver Cancer (Locally Advanced or Metastatic) clinical trials

Study of Tislelizumab as First Treatment for Advanced Lung Cancer

This study looks at how well Tislelizumab works as the first treatment for advanced non-small cell lung cancer that has spread. It aims to understand which treatment strategies after Tislelizumab lead to the best survival outcomes for patients.

DS-8201a plus olaparib for HER2-positive platinum-resistant ovarian cancer

This trial tests whether combining DS-8201a with olaparib can slow or shrink HER2-positive ovarian cancer that has returned quickly after platinum chemotherapy. It’s a Phase 1 study, meaning it mainly checks safety and finds the best dose, while also looking for signs of anti-cancer activity.

Short hormone therapy and radiation for prostate cancer that has spread a little

This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

New drug combination versus standard treatment for advanced colorectal cancer

This trial tests whether a new drug called telisotuzumab adizutecan, given with bevacizumab, works better than the current standard treatment for colorectal cancer that has spread and stopped responding to previous chemotherapy. The goal is to see if this new combination helps patients live longer.

Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer

This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.

Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes

This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.

Testing BMS-986507 for advanced lung and breast cancers

This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.

New treatment for thyroid cancer that spread to neck lymph nodes

This study tests a minimally invasive treatment called irreversible electroporation for thyroid cancer that has come back or spread to lymph nodes in the neck. It may be an option for people who can't have another surgery or for whom radioactive iodine therapy hasn't worked.

Testing a new drug combo for advanced colorectal cancer

This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.

PM8002 plus chemo for untreated metastatic colorectal cancer

This trial tests a new combination therapy (PM8002 plus chemotherapy) for people with metastatic colorectal cancer who have not had prior treatment. It may be an option if your cancer is not MSI-H/dMMR and you are in good overall health.

Study of VVD-133214 for advanced solid tumors

This trial tests an experimental drug called VVD-133214, alone or with other medicines, in people with advanced solid tumors that have specific DNA repair problems (MSI-H/dMMR). The goal is to see if it is safe and effective.

NK cells with or without naxitamab for GD2-positive breast cancer

This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.

Study of BG-75202 for advanced solid tumors

This trial tests a new drug called BG-75202, alone or with other drugs, for people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. It may offer a new option when other treatments have failed.

Testing BNT116 for advanced non-small cell lung cancer

This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.

PD-L1 antibody drug study for advanced lung and head/neck cancers

This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.

Eye tests for people taking Tivdak for cervical cancer

This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.

Asciminib for HER2+ breast cancer that has spread to the brain

This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.

Study of a new drug vs docetaxel for advanced lung cancer

This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.

Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer

This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.

Testing a new drug for advanced cancers with gene changes

This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.

Genetic profiling to guide treatment for advanced solid tumors

This study tests whether analyzing the DNA of your tumor (from a tissue sample or blood draw) can help find the best treatment for your advanced cancer. Researchers will look for genetic changes that could make you eligible for targeted therapy or a clinical trial.

Study of petosemtamab plus chemo for left-sided colorectal cancer

This trial tests a new drug (petosemtamab) plus standard chemo to see if it works better than the current standard (cetuximab plus chemo) for people with advanced left-sided colorectal cancer that has not been treated yet. It is for patients whose cancer cells have no RAS or BRAF mutations.